Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial.

Détails

ID Serval
serval:BIB_75032FE13EF2
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial.
Périodique
International journal of radiation oncology, biology, physics
Auteur(s)
Leimgruber A., Ostermann S., Yeon E.J., Buff E., Maeder P.P., Stupp R., Meuli R.A.
ISSN
0360-3016
Statut éditorial
Publié
Date de publication
2006
Peer-reviewed
Oui
Volume
64
Numéro
3
Pages
869-75
Langue
anglais
Notes
Publication types: Clinical Trial, Phase II ; Journal Article - Publication Status: ppublish
Résumé
PURPOSE: This study was performed to determine the impact of perfusion and diffusion magnetic resonance imaging (MRI) sequences on patients during treatment of newly diagnosed glioblastoma. Special emphasis has been given to these imaging technologies as tools to potentially anticipate disease progression, as progression-free survival is frequently used as a surrogate endpoint. METHODS AND MATERIALS: Forty-one patients from a phase II temolozomide clinical trial were included. During follow-up, images were integrated 21 to 28 days after radiochemotherapy and every 2 months thereafter. Assessment of scans included measurement of size of lesion on T1 contrast-enhanced, T2, diffusion, and perfusion images, as well as mass effect. Classical criteria on tumor size variation and clinical parameters were used to set disease progression date. RESULTS: A total of 311 MRI examinations were reviewed. At disease progression (32 patients), a multivariate Cox regression determined 2 significant survival parameters: T1 largest diameter (p < 0.02) and T2 size variation (p < 0.05), whereas perfusion and diffusion were not significant. CONCLUSION: Perfusion and diffusion techniques cannot be used to anticipate tumor progression. Decision making at disease progression is critical, and classical T1 and T2 imaging remain the gold standard. Specifically, a T1 contrast enhancement over 3 cm in largest diameter together with an increased T2 hypersignal is a marker of inferior prognosis.
Mots-clé
Analysis of Variance, Antineoplastic Agents, Alkylating, Brain Neoplasms, Dacarbazine, Diffusion Magnetic Resonance Imaging, Disease Progression, Female, Glioblastoma, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Prospective Studies
Pubmed
Web of science
Open Access
Oui
Création de la notice
11/04/2008 9:23
Dernière modification de la notice
08/05/2019 20:29
Données d'usage